NYSE:SQZ SQZ Biotechnologies (SQZ) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 07/27/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About SQZ Biotechnologies Stock (NYSE:SQZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SQZ Biotechnologies alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0252-Week Range$0.25▼$3.56Volume1,100 shsAverage Volume455,220 shsMarket Capitalization$707.78 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview SQZ Biotechnologies (NYSE: SQZ) is a clinical‐stage biotechnology company that specializes in the development of novel cell therapies for oncology and infectious diseases. The company’s proprietary Cell Squeeze® platform uses a microfluidic device to temporarily open pores in cell membranes, enabling the delivery of proteins, peptides, mRNA and other cargo directly into the cytosol without relying on viral or chemical vectors. This approach aims to generate potent antigen‐presenting cells and engineered T cells while reducing manufacturing complexity and safety concerns common to viral‐based methods. The company’s pipeline includes both oncology and infectious disease programs. Key programs include an HPV‐targeted antigen‐presenting cell therapy designed to stimulate a robust immune response against HPV16‐associated malignancies and a series of CAR‐T candidates engineered via the Cell Squeeze platform for solid tumors. SQZ Biotechnologies has collaborations with academic institutions and biopharmaceutical partners to advance preclinical and clinical studies, with the goal of demonstrating proof‐of‐concept in a range of indications. Founded in 2014 and headquartered in Cambridge, Massachusetts, SQZ Biotechnologies completed its transition to a publicly traded company in 2021 through a merger with a special purpose acquisition company. The company operates a dedicated manufacturing facility in the Greater Boston area and continues to expand research partnerships to validate its platform across multiple cell therapy modalities. As SQZ advances its lead candidates through regulatory filings and clinical trials, it aims to redefine the delivery and engineering of cell‐based medicines for patients worldwide.AI Generated. May Contain Errors. Read More Receive SQZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SQZ Stock News HeadlinesArsenal Yards attracts another life sciences tenantApril 23, 2026 | bizjournals.comSQZB SQZ Biotechnologies Company - Seeking AlphaJuly 9, 2025 | seekingalpha.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 28 at 1:00 AM | Porter & Company (Ad)SQZ Biotechnologies Co Ordinary SharesDecember 23, 2024 | morningstar.comMPortal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA VenturesDecember 19, 2024 | finance.yahoo.comWhat is the price tag to keep the biotech engine humming in Massachusetts?July 23, 2024 | msn.comSQZ Biotechnologies Company (SQZB)May 22, 2024 | finance.yahoo.comSqz Bio (SQZB) Earnings Dates & ReportsMay 8, 2024 | investing.comSee More Headlines SQZ Stock Analysis - Frequently Asked Questions How have SQZ shares performed this year? SQZ Biotechnologies' stock was trading at $0.0240 at the beginning of 2026. Since then, SQZ shares have increased by 0.0% and is now trading at $0.0240. How were SQZ Biotechnologies' earnings last quarter? SQZ Biotechnologies (NYSE:SQZ) released its earnings results on Wednesday, November, 10th. The company reported ($8.00) earnings per share for the quarter, missing analysts' consensus estimates of ($5.60) by $2.40. The firm earned $4.76 million during the quarter, compared to the consensus estimate of $11.64 million. SQZ Biotechnologies had a negative net margin of 369.96% and a negative trailing twelve-month return on equity of 119.83%. When did SQZ Biotechnologies' stock split? SQZ Biotechnologies shares reverse split before market open on Friday, July 7th 2023.The 1-10 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did SQZ Biotechnologies IPO? SQZ Biotechnologies (SQZ) raised $75 million in an IPO on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of SQZ Biotechnologies? Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SQZ Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include Minerva Neurosciences (NERV), Illumina (ILMN), NVIDIA (NVDA), Oramed Pharmaceuticals (ORMP), Absci (ABSI), Allogene Therapeutics (ALLO) and Beam Therapeutics (BEAM). Company Calendar Last Earnings11/10/2021Today7/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryTransportation Current SymbolNYSE:SQZ CIK1604477 Webwww.sqzbiotech.com Phone617-758-8672FaxN/AEmployees1,620Year Founded2013Profitability EPS (Trailing Twelve Months)($2.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.46 million Net Margins-369.96% Pretax Margin-408.99% Return on Equity-119.83% Return on Assets-59.90% Debt Debt-to-Equity RatioN/A Current Ratio3.50 Quick Ratio3.50 Sales & Book Value Annual Sales$18.16 million Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.01Miscellaneous Outstanding Shares29,491,000Free Float24,772,000Market Cap$707.78 thousand OptionableNot Optionable Beta2.34 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:SQZ) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SQZ Biotechnologies Please log in to your account or sign up in order to add this asset to your watchlist. Share SQZ Biotechnologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
